Experts Unite in New York; Discuss Hepatitis C and New Treatment Developments

Wednesday, October 8, 2008 General News J E 4

Oct. 7

WHAT: Science Writers' Workshop on Hepatitis C: The Hidden Epidemic hosted by the Hepatitis Foundation International WHEN: Thursday, October 16, 2008 WHERE: New York Academy of Sciences in Manhattan WHO: Clinicians, researchers and patients will join the Hepatitis Foundation International for this important discussion about hepatitis C and promising therapies on the horizon. Keynote speakers include: Ira M. Jacobson, MD Medical Director of the Center for the Study of Hepatitis C Professor of Clinical Medicine Weill Cornell Medical College of Cornell University Raymond S. Koff, MD Clinical Professor of Medicine University of Connecticut School of Medicine WHY: As the nation's most common blood-borne infection and one of the most significant health problems affecting the liver, hepatitis C is estimated to affect some 4 million Americans in its chronic form. It is the leading cause of chronic liver disease, death from liver disease and liver transplant. While advances in medicine and treatment have been made, disease management remains a challenge for many patients. Today, the treatment of hepatitis C stands squarely on the verge of a major breakthrough. New therapies in late stage development show high and lasting viral clearance rates, better patient tolerability and shorter treatment duration. Come hear more about these exciting new advances from the experts in advance of the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in October. RSVP: Marissa Nelson 212-477-9007 ext. 21

SOURCE Hepatitis Foundation International


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Dental One Acquired by MSD Capital and North Peak ...
In Vivo Data on Taligen Therapeutics' Pipeline Can...